8,310 Shares in Moderna, Inc. $MRNA Purchased by N.F.U. MUTUAL UNIT MANAGERS Ltd

N.F.U. MUTUAL UNIT MANAGERS Ltd purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 8,310 shares of the company’s stock, valued at approximately $1,599,000.

Other hedge funds have also recently modified their holdings of the company. BlackRock Inc. purchased a new position in Moderna in the 2nd quarter valued at $2,142,877,000. Theleme Partners LLP acquired a new position in Moderna in the 2nd quarter valued at $564,272,000. Merck & Co. Inc. acquired a new position in Moderna in the 2nd quarter valued at $161,642,545. Bamco Inc. NY purchased a new position in Moderna during the 2nd quarter worth $139,317,000. Finally, Bank of New York Mellon Corp purchased a new position in Moderna during the 2nd quarter worth $119,168,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Moderna news, President Stephen Hoge sold 39,215 shares of the business’s stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $211.61, for a total transaction of $8,298,286.15. Following the sale, the president directly owned 1,311,095 shares in the company, valued at approximately $277,440,812.95. The trade was a 2.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider directly owned 74,129 shares in the company, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 275,626 shares of company stock worth $50,776,076. Corporate insiders own 10.80% of the company’s stock.

Moderna Stock Down 2.6%

Moderna stock opened at $194.18 on Friday. The stock’s 50 day moving average price is $207.87 and its 200 day moving average price is $100.37. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $280.80. The company has a market cap of $78.57 billion, a PE ratio of -27.35 and a beta of 1.16. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47.

Moderna (NASDAQ:MRNA – Get Free Report) last released its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $1.48. The firm had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $890.25 million. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. Moderna’s revenue was up 29.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.51) earnings per share. On average, sell-side analysts predict that Moderna, Inc. will post -5.23 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. The Goldman Sachs Group raised their target price on shares of Moderna from $137.00 to $195.00 and gave the stock a “neutral” rating in a research note on Monday, November 9th. Jefferies Financial Group reiterated a “hold” rating and set a $150.00 price target (up from $60.00) on shares of Moderna in a research note on Wednesday, August 19th. Citigroup reiterated a “sell” rating on shares of Moderna in a research note on Friday, October 23rd. Evercore increased their price target on shares of Moderna from $50.00 to $80.00 in a report on Thursday, October 8th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Moderna in a research report on Friday, September 25th. Six analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $120.25.

Read Our Latest Stock Report on MRNA

More Moderna News

These are some of the MRNA news items that stood out recently:

  • Negative Sentiment: Investors are concerned that Moderna’s 2027 cash costs could reach $4 billion. The spending burden, alongside uncertain revenue from its expanding vaccine and oncology pipeline, raises questions about funding its next phase of growth. Article: Moderna's 2027 Cash Costs
  • Negative Sentiment: President Stephen Hoge sold shares in transactions reported for November 16 and 17, and coverage noted the stock fell below its 50-day moving average. The sales were made under a pre-arranged Rule 10b5-1 plan, so they do not necessarily signal a change in his view of the company, but they may add to near-term selling pressure. Article: Moderna President Sells Shares
  • Neutral Sentiment: Bireme Capital disclosed that it sold its Moderna position after the stock’s rally. That reflects one manager’s portfolio decision, rather than a company announcement. Article: Bireme Capital Sold Moderna

About Moderna

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Featured Stories

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.